| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10217722 | Digestive and Liver Disease | 2018 | 10 Pages |
Abstract
HBIG can be safely discontinued in HBsAgpositive LT recipients and replaced by ETV or TDF monotherapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Matteo A. Manini, Gavin Whitehouse, Matthew Bruce, Matteo Passerini, Tiong Y. Lim, Ivana Carey, Aisling Considine, Pietro Lampertico, Abid Suddle, Nigel Heaton, Michael Heneghan, Kosh Agarwal,